EANS-News: Marseille-Kliniken AG Resolutions of extraordinary general meeting
support the strategic reorientation of Marseille-Kliniken AG
--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
Annual & Special Corporate Meetings/Results Extraordinary General Meeting
Hamburg, Germany (euro adhoc) - 19 October 2012 - The extraordinary general
meeting of Marseille-Kliniken AG held today at its headquarter in Hamburg
approved all applications introduced by the company's administration with a
majority of more than 99 percent. The attending shareholders represented more
than 67 percent of the share capital.
With the approved shift from Regulated Market (Prime Standard) to Entry Standard
as part of the Open Market at the Frankfurt Stock Exchange, Marseille-Kliniken
AG consistently resumes its strategic reorientation and internal reorganization.
The change reflects the company's recent development, as it owns a much leaner
competitive position after the business segments rehabilitation and acute care
have been disinvested or abandoned according to plan. Therefore the Entry
Standard appears to be the appropriate listing segment. The principal stock
market listing in Frankfurt and the respective trading hours will however remain
unchanged.
The company's streamlining is furthermore represented by an approved amendment
of the statutes for a future reduction of the supervisory board from previously
six to than three members. In this context following the extraordinary general
meeting today Messrs Uwe Bergheim and Prof. Dr. med. Matthias P. Schönermark
have already announced their intention to resign from office after the end of
the annual general meeting which is planned for 3 December 2012. Another
amendment of the statutes builds furthermore the basis for a future adjustment
and new regulation of the compensation for the members of the supervisory board.
Michael Thanheiser, chairman of Marseille-Kliniken AG, comments on the
resolutions of the extraordinary general meeting as follows: "We wanted to give
our shareholders the possibility to decide for their own about the adequate
listing segment. The clear vote for the shift to Entry Standard is consistent
with our company's recent development, as our strategic reorientation aims at
streamlining the business and realising increases in efficiency. The same
applies for the reduction of the supervisory board. Both resolutions of our
shareholders are therefore also a confirmation of our corporate strategy."
-- End of Corporate News ---
About Marseille-Kliniken AG:
Marseille-Kliniken AG (ISIN DE0007783003, WKN 778300, MKA) with its 57
residential care facilities, three residential units for assisted living and
about 4,700 employees is a market leading listed company on health care in
Germany. The business model is significantly influenced by the demographic
development. Therefore Marseille-Kliniken AG has a secured future. Short-term
economic fluctuations on the other hand exert only a minor influence. As a
consistently modern company with strong focus on quality, the private enterprise
is in a good position within a competitive environment primarily characterized
by regionally active charities.
Further inquiry note:
Hillermann Consulting
Jan Pahl
Investor Relations for Marseille-Kliniken AG
Poststraße 14-16
20354 Hamburg
Germany
Tel.: +49-(0)40 / 3202791-0
www.marseille-kliniken.de
end of announcement euro adhoc
--------------------------------------------------------------------------------
company: Marseille-Kliniken AG
Alte Jakobstraße 79/80
D-10179 Berlin
phone: +49 (0)30 246 32-400
FAX: +49 (0)30 246 32-401
mail: info@marseille-kliniken.de
WWW: http://www.marseille-kliniken.de
sector: Pharmaceuticals
ISIN: DE0007783003
indexes: CDAX, Classic All Share, Prime All Share
stockmarkets: free trade: Berlin, Düsseldorf, Stuttgart, regulated dealing:
Hamburg, regulated dealing/prime standard: Frankfurt
language: English